Peripheral neuropathies after BRAF and/or MEK inhibitor treatment: A pharmacovigilance study.
Br J Clin Pharmacol
; 88(11): 4941-4949, 2022 11.
Article
en En
| MEDLINE
| ID: mdl-36028463
ABSTRACT
Reports suggested the potential occurrence of peripheral neuropathies (PN) in patients treated with BRAF (BRAFi) and/or MEK inhibitors (MEKi) for BRAF-activated tumours. We aimed to better characterize these PN. We queried the French pharmacovigilance database for all cases of PN attributed to BRAFi and/or MEKi. Fifteen patients were identified. Two main clinical PN phenotypes were seen. Six patients presented a length-dependent, axonal polyneuropathy symptoms were mostly sensory and affecting the lower limbs; management and outcome were variable. Nine patients developed a demyelinating polyradiculoneuropathy symptoms affected the four limbs and included hypoesthesia, weakness and ataxia; cranial nerves were involved in four cases; most patients received intravenous immunoglobulins or glucocorticoids, with variable outcome; one patient was rechallenged with a different BRAFi/MEKi combination with a rapid relapse in symptoms. In conclusion, patients under BRAFi/MEKi therapy may develop treatment-induced PN. Two main phenotypes can occur a symmetric, axonal, length-dependent polyneuropathy and a demyelinating polyradiculoneuropathy.
Palabras clave
Texto completo:
1
Base de datos:
MEDLINE
Asunto principal:
Polineuropatías
/
Polirradiculoneuropatía
/
Enfermedades del Sistema Nervioso Periférico
Tipo de estudio:
Prognostic_studies
Límite:
Humans
Idioma:
En
Revista:
Br J Clin Pharmacol
Año:
2022
Tipo del documento:
Article
País de afiliación:
Francia